Possibilities of optimizing therapy of heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonists

The article presents a systematic review of the literature devoted to the analysis of the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in chronic heart failure with preserved ejection fraction (HFpEF). The research question concerned the possibilities of co-administration of drugs from the groups of sodium-glucose cotransporter-2 inhibitors (iSGLT-2) and GLP-1 RA. The literature was searched in the PubMed system. The final analysis included 11 studies relevant to the topic under study. According to the analysis, GLP-1 RA is an effective treatment for patients with CHF, leading to a reduction in HF symptoms and an improvement in the quality of life of such patients. The issues of simultaneous administration of GLP-1 RA and iSGLT-2 have been studied in sufficient detail in patients with type 2 diabetes mellitus: the effectiveness and safety of such a combination have been demonstrated. In the absence of diabetes in patients with HF, optimization of treatment using the GLP-1 RA class requires additional specially planned studies. The article presents a systematic review of the literature devoted to the analysis of the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in chronic heart failure with preserved ejection fraction (HFpEF). The research question concerned the possibilities of co-administration of drugs from the groups of sodium-glucose cotransporter-2 inhibitors (iSGLT-2) and GLP-1 RA. The literature was searched in the PubMed system. The final analysis included 11 studies relevant to the topic under study. According to the analysis, GLP-1 RA is an effective treatment for patients with CHF, leading to a reduction in HF symptoms and an improvement in the quality of life of such patients. The issues of simultaneous administration of GLP-1 RA and iSGLT-2 have been studied in sufficient detail in patients with type 2 diabetes mellitus: the effectiveness and safety of such a combination have been demonstrated. In the absence of diabetes in patients with HF, optimization of treatment using the GLP-1 RA class requires additional specially planned studies.

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. Erratum in: Lancet. 2019;393(10190):e44. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.

2. Galyavich A.S., Tereshchenko S.N., Uskach T.M., Ageev F.T., Aronov D.M., Arutyunov G.P., et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi: 10.15829/1560-4071-2024-6162

3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. Erratum in: Circulation. 2022;145(18):e1033. Erratum in: Circulation. 2022;146(13):e185. Erratum in: Circulation. 2023;147(14):e674. doi: 10.1161/CIR.0000000000001063.

4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Erratum in: Eur Heart J. 2021;42(48):4901. doi: 10.1093/eurheartj/ehab368.

5. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi: 10.1056/NEJMoa2206286

6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038

7. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. Erratum in: Eur Heart J. 2024;45(1):53. doi: 10.1093/eurheartj/ehad195.

8. Cherkashin D.V., Salukhov V.V., Khalimov Y.S. Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention. Meditsinskiy sovet = Medical Council. 2025;19(13):157-172. (In Russ.) https://doi.org/10.21518/ms2025-323

9. Aryee EK, Ozkan B, Ndumele CE. Heart Failure and Obesity: The Latest Pandemic. Prog Cardiovasc Dis. 2023;78:43-48. doi: 10.1016/j.pcad.2023.05.003

10. Vest AR, Schauer PR, Rodgers JE, Sanderson E, LaChute CL, Seltz J, et al. Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC Heart Fail. 2024;12(9):1509-1527. doi: 10.1016/j.jchf.2024.06.006

11. Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum. Heart Fail Rev. 2025;30(3):515-523. doi: 10.1007/s10741-025-10481-7

12. Inciardi RM, Riccardi M, Savarese G, Metra M, Vaduganathan M, Solomon SD. Tailoring medical therapy for heart failure with preserved ejection fraction. Eur J Heart Fail. 2025;27(2):190-193. doi: 10.1002/ejhf.3558

13. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827

14. Lopez J, Makuvire T, Davis JD, Carbone S. The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. US Cardiol. 2025;19:e12. doi: 10.15420/usc.2024.44

15. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141

16. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X

17. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3

18. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896-907. doi: 10.1056/NEJMoa2108269

19. Popov S.V., Boshchenko A.A., Maslov L.N., Zhuravleva O.A., Mukhomedzyanov A.V., Slidnevskaya A.S., et al. Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1. Siberian Journal of Clinical and Experimental Medicine. 2025;40(3):11-18. (In Russ.) doi: 10.1016/j.cmet.2016.06.009

20. Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15-30. doi: 10.1016/j.cmet.2016.06.009

21. Smits MM, Van Raalte DH. Corrigendum: Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:786732. Erratum for: Front Endocrinol (Lausanne). 2021;12:645563. doi: 10.3389/fendo.2021.786732.

22. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563

23. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3

24. Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811

25. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023;11(8 Pt 1):1000-1010. doi: 10.1016/j.jchf.2023.05.010

26. Harrington J. STEP HFpEF DM: a sweet sequel. Heart Fail Rev. 2024;29(5):913-915. doi: 10.1007/s10741-024-10408-8

27. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0

28. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X

29. Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0

30. Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545

31. Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. Erratum in: Lancet Diabetes Endocrinol. 2019;7(5):e5. Erratum in: Lancet Diabetes Endocrinol. 2019;7(8):e20. Erratum in: Lancet Diabetes Endocrinol. 2019;7(11):e22. doi: 10.1016/S2213-8587(19)30066-X

32. Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, et al. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019;10(6):1518-1526. doi: 10.1111/jdi.13066

33. Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2022;145(8):565-574. Erratum in: Circulation. 2023;147(23):e720. doi: 10.1161/CIRCULATIONAHA.121.057934.

34. Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial. Diabetes Obes Metab. 2024;26(5):1624-1635. doi: 10.1111/dom.15464

35. Katogiannis K, Thymis J, Kousathana F, Pavlidis G, Korakas E, Kountouri A, et al. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function. Medicina (Kaunas). 2024;60(3):395. doi: 10.3390/medicina60030395

36. Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020;318:126-129. doi: 10.1016/j.ijcard.2020.06.011

37. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. 2025;48(11):1904-1913. doi: 10.2337/dc25-1673

38. Sivalingam S, Wasehuus VS, Rotbain Curovic V, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54-64. doi: 10.1111/dom.15287

39. Chen SY, Wu JY, Liao KM, Lin YM. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(4):324-333. doi: 10.1093/ehjcvp/pvaf014.

40. Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nóvoa F, et al. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. J Clin Endocrinol Metab. 2023;109(1):4-9. doi: 10.1210/clinem/dgad398

41. Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4.